Abrogation of KLF5 sensitizes BRCA1-proficient pancreatic cancer to PARP inhibition

Abrogation of KLF5 sensitizes BRCA1-proficient pancreatic cancer to PARP inhibition

Poly ADP-ribose polymerase (PARP) inhibitor monotherapies are selectively effective in patients with pancreatic, breast, prostate, and ovarian cancers with BRCA1 mutations. Cancer patients with more frequent wild-type BRCA show poor responses to PARP inhibitors. Moreover, patients who are initially...

Full description

Bibliographic Details
Main Authors: Zhang Zheng, Liu Yuxin, Xu Yaolin, Xu Zijin, Jia Jinbin, Jin Yun, Wang Wenquan, Liu Liang
Format: Article
Language:English
Published: China Science Publishing & Media Ltd. 2024-03-01
Series:Acta Biochimica et Biophysica Sinica
Subjects:
pancreatic cancer
wild-type <italic>BRCA</italic>
BRCAness
KLF5
BRCA1
Online Access:https://www.sciengine.com/doi/10.3724/abbs.2023288

Internet

https://www.sciengine.com/doi/10.3724/abbs.2023288

Similar Items